As Covid-19 cases fall, so do sales of favipiravir and remdesivir drugs

While remdesivir is an injectable drug which is administered in hospital settings, antiviral drug favipiravir is given orally

After peaking in the second half of last year, sales of two key Covid-19 drugs — favipiravir and remdesivir — have fallen sharply. 

Data from market research firm AIOCD AWACS shows that from a peak monthly sales of Rs 124 crore in November last year, sales of remdesivir have fallen to Rs 41 crore in January. 

Cipla’s Cipremi and Cadila Healthcare’s Remdac have been the top selling brands in the last few months. In January, too, the two brands sold worth Rs 15 crore each, accounting for 75 per cent of the total monthly sales of remdesivir.  Sales, however, have dipped for